Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.
Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.
Amphastar Pharmaceuticals announced that its CFO, Bill Peters, and EVP of Corporate Administration, Jacob Liawatidewi, will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for June 6, 2024, at 12:30 pm EST. The discussion will be moderated by an analyst and focus on the company's strategic initiatives and financial outlook. Investors can access the webcast through Amphastar's website, which will be available for 30 days following the presentation.
Amphastar Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol. This product treats and prevents bronchospasm in patients aged four and older and is bioequivalent to Teva's ProAir® HFA. Amphastar plans to launch the product in Q3 2024. The U.S. market for branded and generic albuterol sulfate inhalation aerosols was approximately $1.7 billion as of March 2024. Amphastar also has three ANDAs, three biosimilar products, and four generic products in development, targeting markets worth over $11.4 billion. The approval underscores Amphastar’s manufacturing capabilities and commitment to developing complex inhalation products.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will have Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, join an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on May 15th, 2024. The webcast will be accessible for 30 days on Amphastar's Pharmaceuticals website.
Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024. The company achieved GAAP net income of $43.2 million and adjusted non-GAAP net income of $55.3 million. Notable highlights include BAQSIMI revenue growth of 22% over the first quarter of 2023. The company experienced positive sales increases in several key products like Glucagon, Epinephrine, and Primatene MIST ®. However, there were decreases in sales of Lidocaine, Enoxaparin, and Naloxone. The company's gross profit margin was 52.4% of net revenues, driven by factors like increased sales of higher-margin products. Amphastar's financial performance demonstrates a strong first quarter with promising growth potential.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will release its first quarter earnings for 2024 on May 8, 2024. The company focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products. They also sell insulin API products primarily used in hospital settings. The conference call to discuss financial results will be held at 2:00 p.m. Pacific Time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.